Patents Assigned to Santen Pharmaceutical Co. Ltd.
  • 2-[[[2-[(HYDROXYACETYL)AMINO]-4-PYRIDINYL]METHYL]THIO]-N-[4-(TRIFLUOROMETHOXY)PHENYL]-3-PYRIDINECARBOXAMIDE BENZENESULFONATE, CRYSTAL OF SAME, CRYSTAL POLYMORPH THEREOF, AND METHODS FOR PRODUCTION THEREOF
    Publication number: 20160251314
    Abstract: In the course of developing 2-[[[2-[(hydroxyacetyl) amino]-4-pyridinyl] methyl] thio]-N-[4-(trifluoromethoxy) phenyl]-3-pyridinecarboxamide (compound A), there are the multiple problems: 1) compound A or its salt is difficult to be recrystallized, the storage stability largely differs depending on the kind of the salt, and it is very difficult to obtain a salt of compound A having excellent storage stability; 2) in a crystallization process of compound A, it is very difficult to control a crystal polymorph, and 3) compound A (free body) causes mineral deposition in the stomach when it is orally administered repeatedly.
    Type: Application
    Filed: May 10, 2016
    Publication date: September 1, 2016
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Masashi NIWA, Hiroshi DEGUCHI
  • Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
    Patent number: 9415038
    Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl(6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: August 16, 2016
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Naveed Shams, Henk-Andre Kroon, Hisashi Kawata, Noriko Kawabata
  • COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA COMPRISING A SULFONAMIDE COMPOUND AND ANOTHER DRUG
    Publication number: 20160228421
    Abstract: A composition for preventing or treating glaucoma or ocular hypertension including a combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl} pyridin-2-ylamino) acetate and at least one other drug for preventing or treating glaucoma or ocular hypertension, with the proviso that tafluprost is excluded.
    Type: Application
    Filed: April 19, 2016
    Publication date: August 11, 2016
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Tomoko KIRIHARA, Atsushi SHIMAZAKI, Masatsugu NAKAMURA
  • POLYETHYLENE GLYCOL-CONTAINING COMPOSITION
    Publication number: 20160228420
    Abstract: The present invention relates to a pharmaceutical composition comprising a compound represented by the formula (1) or a salt thereof and polyethylene glycol.
    Type: Application
    Filed: September 18, 2014
    Publication date: August 11, 2016
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Kenji Murai, Kazuhito Yamada
  • PRODUCTION METHOD FOR 3,3-DIMETHYL-3,4-DIHYDRO-1H-QUINOXALIN-2-ONE DERIVATIVE AND INTERMEDIATE FOR SAID PRODUCTION METHOD
    Publication number: 20160200690
    Abstract: An object is to provide a novel production method suitable for industrial production of a 3,3-dimethyl-3,4-dihydro-1H-quinoxalin-2-one derivative and a synthetic intermediate for the method.
    Type: Application
    Filed: August 8, 2014
    Publication date: July 14, 2016
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Kazuhiro KUDOU, Masato NAGATSUKA
  • Rapamycin formulations and methods of their use
    Patent number: 9387165
    Abstract: Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: July 12, 2016
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Sreenivasu Mudumba, Philippe J M Dor, Thierry Nivaggioli, David A. Weber, Sidiq Farooq
  • Liquid formulations for treatment of diseases or conditions
    Patent number: 9381153
    Abstract: Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; liquid formulations comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration in a subject.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: July 5, 2016
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Sreenivasu Mudumba, Philippe J M Dor, Thierry Nivaggioli, David A. Weber, Sidiq Farooq
  • 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzenesulfonate, crystal of same, crystal polymorph thereof, and methods for production thereof
    Patent number: 9359328
    Abstract: In the course of developing 2-[[[2-[(hydroxyacetyl) amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy) phenyl]-3-pyridinecarboxamide(compound A), there are the multiple problems: 1) compound A or its salt is difficult to be recrystallized, the storage stability largely differs depending on the kind of the salt, and it is very difficult to obtain a salt of compound A having excellent storage stability; 2) in a crystallization process of compound A, it is very difficult to control a crystal polymorph, and 3) compound A (free body) causes mineral deposition in the stomach when it is orally administered repeatedly.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: June 7, 2016
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Masashi Niwa, Hiroshi Deguchi
  • Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
    Patent number: 9339496
    Abstract: A composition for treating or preventing glaucoma or ocular hypertension including a isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate and a beta-receptor antagonist, in a combined pharmaceutically acceptable amount. As for the administration form, these drugs may be administered concomitantly or may be administered as a combination drug.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: May 17, 2016
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Tomoko Kirihara, Atsushi Shimazaki, Masatsugu Nakamura
  • OPHTHALMIC SOLUTIONS
    Publication number: 20160106757
    Abstract: An ophthalmic formulation which is an aqueous solution of a prostaglandin derivative, the prostaglandin derivative being 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F2 ? or an isopropyl ester thereof, said prostaglandin derivative being contained in the aqueous solution as an active ingredient in a concentration of 0.00005 to 0.05 weight %, a nonionic surfactant which is polysorbate 80 in a concentration in the solution of 10 times or more to 100 times or less of the prostaglandin derivative and an antioxidant in an amount sufficient to inhibit decomposition of the prostaglandin derivative.
    Type: Application
    Filed: December 28, 2015
    Publication date: April 21, 2016
    Applicants: SANTEN PHARMACEUTICAL CO., LTD., ASAHI GLASS COMPANY, LIMITED
    Inventors: Kenji MORISHIMA, Akio KIMURA, Hiroyuki ASADA, Masayuki UMEDA, Mitsuaki KUWANO
  • THERAPEUTIC AGENT FOR MEIBOMIAN GLAND DYSFUNCTION
    Publication number: 20160022648
    Abstract: A compound represented by the formula (1): wherein R1 represents a hydroxyl group, a dimethylphosphynoyloxy group, etc.; and R2 and R3 represent a methoxy group, etc., or a pharmaceutically acceptable salt thereof can reduce a score of telangiectasia around the meibomian gland orifices and a number of obstruction at the orifices, so that it is useful as a prophylactic and/or therapeutic agent for meibomian gland dysfunction.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 28, 2016
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Hideki MIYAKE, Tomoko ODA, Daisuke SHII
  • PROPHYLACTIC OR THERAPEUTIC AGENT FOR POSTERIOR OCULAR DISEASE CONTAINING TETRAHYDROPYRANYLAMINOCYCLOPENTYLCARBONYLTETRAHYDROPYRIDOPYRIDINE DERIVATIVE AS EFFECTIVE INGREDIENT
    Publication number: 20160008333
    Abstract: The present invention relates to a prophylactic or therapeutic agent for a posterior ocular disease containing the compound represented by a formula (1), its enantiomer or diastereomer, or their pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Application
    Filed: February 27, 2014
    Publication date: January 14, 2016
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Atsushi YOSHIDA, Sae AKAO, Shinji YONEDA, Komei OKABE, Tomomi KOHARA
  • 2-[[[2-[(HYDROXYACETYL)AMINO]-4-PYRIDINYL]METHYL]THIO]-N-[4-(TRIFLUOROMETHOXY)PHENYL]-3-PYRIDINECARBOXAMIDE BENZENESULFONATE, CRYSTAL OF SAME, CRYSTAL POLYMORPH THEREOF, AND METHODS FOR PRODUCTION THEREOF
    Publication number: 20150291560
    Abstract: In the course of developing 2-[[[2-[(hydroxyacetyl) amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy) phenyl]-3-pyridinecarboxamide(compound A), there are the multiple problems: 1) compound A or its salt is difficult to be recrystallized, the storage stability largely differs depending on the kind of the salt, and it is very difficult to obtain a salt of compound A having excellent storage stability; 2) in a crystallization process of compound A, it is very difficult to control a crystal polymorph, and 3) compound A (free body) causes mineral deposition in the stomach when it is orally administered repeatedly.
    Type: Application
    Filed: April 14, 2015
    Publication date: October 15, 2015
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Masashi NIWA, Hiroshi DEGUCHI
  • Method for protecting a retinal neuronal cell
    Patent number: 9138438
    Abstract: A method of protecting a retinal neuronal cell by administering an effective amount of a prostaglandin F2? derivative to a patient. A method of preventing or treating an eye disease associated with retinal neuronal cell damage by administering a therapeutically effective amount of a prostaglandin F2? derivative to a patient.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: September 22, 2015
    Assignees: ASAHI GLASS COMPANY, LIMITED, SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Naruhiro Ishida, Atsushi Shimazaki
  • Intraocular lens implantation device
    Patent number: D737430
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: August 25, 2015
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Christian Winfried Wargner, Yoshitaka Yamada, Katsuyuki Ueno
  • Intraocular lens holder
    Patent number: D737957
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: September 1, 2015
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Christian Winfried Wargner, Yoshitaka Yamada, Katsuyuki Ueno
  • Intraocular lens implantation device
    Patent number: D739010
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: September 15, 2015
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Christian Winfried Wargner, Yoshitaka Yamada, Katsuyuki Ueno
  • Lens-holding and guiding implement for intraocular lens implantation device
    Patent number: D747806
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: January 19, 2016
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Christian Winfried Wargner, Yoshitaka Yamada, Katsuyuki Ueno
  • Operation-guiding cylinder for intraocular lens implantation device
    Patent number: D748256
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: January 26, 2016
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Christian Winfried Wagner, Yoshitaka Yamada, Katsuyuki Ueno
  • Intraocular lens implantation device
    Patent number: D754331
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: April 19, 2016
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Christian Winfried Wargner, Yoshitaka Yamada, Katsuyuki Ueno